BACKGROUND: Feline acromegaly has been reported infrequently in the veterinary literature and current knowledge of this endocrinopathy is based on limited numbers of animals with relatively advanced clinical signs. HYPOTHESIS: This study was undertaken to screen diabetic cats for the presence of acromegaly. ANIMALS: Diabetic cats with variable control examined by general practitioners in the United Kingdom. METHODS: Blood samples were screened for the possible presence of acromegaly with basal serum concentrations of insulin-like growth factor 1 (IGF-1) and, when available, feline growth hormone (fGH). In patients with markedly increased IGF-1 concentrations intracranial computed tomography (CT) was offered, and in selected cats additional imaging was performed. RESULTS: IGF-1 was determined in 184 variably controlled diabetic cats; 59 cats had markedly increased IGF-1 concentrations (>1,000 ng/mL; reference interval, 208-443 ng/mL). Eighteen cats subsequently were examined, and acromegaly was confirmed in 17 cats. Notable findings included absence of a detectable pituitary mass lesion in some affected cats regardless of whether CT or magnetic resonance imaging (MRI) was used. Hypertension was not found to be a complication in the evaluated cats and respiratory stridor was more prevalent than previously reported. CONCLUSIONS AND CLINICAL IMPORTANCE: Measurement of IGF-1, growth hormone (GH), or both is useful in the diagnosis of acromegaly in cats.
BACKGROUND:Feline acromegaly has been reported infrequently in the veterinary literature and current knowledge of this endocrinopathy is based on limited numbers of animals with relatively advanced clinical signs. HYPOTHESIS: This study was undertaken to screen diabeticcats for the presence of acromegaly. ANIMALS: Diabeticcats with variable control examined by general practitioners in the United Kingdom. METHODS: Blood samples were screened for the possible presence of acromegaly with basal serum concentrations of insulin-like growth factor 1 (IGF-1) and, when available, feline growth hormone (fGH). In patients with markedly increased IGF-1 concentrations intracranial computed tomography (CT) was offered, and in selected cats additional imaging was performed. RESULTS:IGF-1 was determined in 184 variably controlled diabeticcats; 59 cats had markedly increased IGF-1 concentrations (>1,000 ng/mL; reference interval, 208-443 ng/mL). Eighteen cats subsequently were examined, and acromegaly was confirmed in 17 cats. Notable findings included absence of a detectable pituitary mass lesion in some affected cats regardless of whether CT or magnetic resonance imaging (MRI) was used. Hypertension was not found to be a complication in the evaluated cats and respiratory stridor was more prevalent than previously reported. CONCLUSIONS AND CLINICAL IMPORTANCE: Measurement of IGF-1, growth hormone (GH), or both is useful in the diagnosis of acromegaly in cats.
Authors: Francesco Zublena; Alice Tamborini; Carmel T Mooney; Susan M North; Monika A Lobacz; Dan Andrew; Vanessa Woolhead; Heather Covey; Herbert A Schmid; David B Church; Stijn J M Niessen Journal: Can Vet J Date: 2018-10 Impact factor: 1.008
Authors: Stijn J M Niessen; Yaiza Forcada; Panagiotis Mantis; Christopher R Lamb; Norelene Harrington; Rob Fowkes; Márta Korbonits; Ken Smith; David B Church Journal: PLoS One Date: 2015-05-29 Impact factor: 3.240
Authors: D G O'Neill; R Gostelow; C Orme; D B Church; S J M Niessen; K Verheyen; D C Brodbelt Journal: J Vet Intern Med Date: 2016-06-29 Impact factor: 3.333
Authors: Diego D Miceli; Patricia N Vidal; Gustavo A Pompili; Víctor A Castillo; Elber A Soler Arias; Stijn Jm Niessen Journal: JFMS Open Rep Date: 2021-05-31
Authors: J M Fletcher; C J Scudder; M Kiupel; H N Pipe-Martin; P J Kenny; P Mantis; J Fenn; K Smith; R V Blair; L A Granger; S J M Niessen Journal: J Vet Intern Med Date: 2016-06-03 Impact factor: 3.333